Detailed Narrative
Q1 FY27 Performance Overview
Zota Health Care Limited commenced FY27 with robust growth, reporting a 67.6% year-over-year increase in revenue from operations to INR 173.60 crores. Gross profit reached INR 107.56 crores, with the gross margin improving to 61.96%. The company's Davaindia network expanded significantly, adding 264 new stores to reach a total of 2,825 stores by June 30, 2026, serving nearly 60 lakh customer footfalls.
Davaindia Network Expansion and Strategy
The company's retail footprint expanded by a net of 246 stores in Q1 FY27, including 201 COCO and 63 FOFO stores, while closing 18. This expansion aligns with strategic growth objectives to improve access to affordable healthcare. Management plans to moderate store expansion in Q2 FY27 to focus on productivity and operational trends, aiming for a total of 600-650 new stores for the full FY27.
Marketing Strategy and Expenses
Other expenses saw a notable increase, rising to 33% of revenue in Q1 FY27 from 21% in Q1 FY26. This was primarily driven by marketing investments totaling INR 15-17 crore in Q1 alone, following the onboarding of Mahendra Singh Dhoni as a brand ambassador. Management clarified that this spend is strategic for brand building and awareness, not expected to annualize at the Q1 rate, with a full-year marketing budget projected at INR 40-45 crore for FY27.
Gross Margin Dynamics
Gross margins, while strong at 61.96%, experienced a slight compression compared to the previous quarter. This was attributed to temporary increases in input costs, such as packaging and bottle expenses, influenced by the ongoing geopolitical situation and war. Management anticipates this pressure to be short-lived📎, expecting margins to revert to historical levels and improve over the next one to two quarters.
Profitability and Cash Flow Outlook
The company reported a PBT loss of INR 43-44 crore for Q1 FY27. After adjusting for non-cash items like depreciation and Ind AS-related accounting impacts, and excluding incremental marketing spend, the underlying cash loss for the quarter was approximately INR 20 crore. Management expects to return to reported EBITDA positivity from Q2 FY27 onwards and aims to achieve cash breakeven by Q4 FY27 or Q1 FY28.
Store Maturity and EBITDA Contribution
Stores typically reach maturity within 12-18 months, achieving monthly revenues of INR 2.2-2.5 lakh and store-level EBITDA margins of 12-15%. Older cohorts, such as the 234 stores opened between 2021-2024, are already generating average GMV of INR 4.13 lakh per store per month. Profitability at the store level gradually increases, with 30% EBITDA margins typically achieved after 4-5 years of operation.
New Initiatives: UGO Generic and SKIA
Zota Health Care is investing in new ventures like UGO Generic and SKIA, with INR 2 crore invested in each this quarter. These initiatives are currently in their initial rollout and pilot phases, with management expecting to see gradual progress and measurable movement from these businesses starting next quarter. The goal is to build additional consumer touchpoints and expand the addressable market beyond traditional pharmacy retail.
Market Opportunity in Indian Healthcare
Management highlighted a significant headroom for growth in the Indian pharmacy market, with approximately 18-19 lakh pharmacies nationwide and organized retail (excluding Jan Aushadhi) accounting for only 14,000-15,000. The company sees a huge opportunity in the shift from branded to generic medicines and aims to leverage its first-mover advantage to deepen penetration across the country.